This segment focuses on the research and development of novel therapeutics for neurological disorders, with a primary focus on addressing unmet needs in this area. The company's lead product in this segment is MCT-125, a Phase II therapeutic candidate designed to treat primary multiple sclerosis-related fatigue. Research and development activities include clinical trials, formulation development, and exploring the mechanisms of action of the drug. The company utilizes advanced drug development methodologies and collaborates with research organizations to advance its neurological programs. The patient impact is significant, as MCT-125 aims to alleviate debilitating fatigue, improving the quality of life for multiple sclerosis patients. Market positioning is based on addressing a significant unmet need in the treatment of MS-related fatigue. Future opportunities include expanding the application of MCT-125 to other neurological conditions. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials to demonstrate efficacy and safety. Partnerships with research institutions and pharmaceutical companies are crucial for advancing the development and commercialization of neurological therapeutics.

This segment is dedicated to the development of innovative cancer treatments, leveraging advanced technologies to target and eliminate cancer cells. The company's primary focus is on developing dsRNA (double-stranded RNA) therapeutics. MCT-465 is a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-485 is a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. Research and development activities include preclinical studies, formulation development, and exploring the mechanisms of action of dsRNA therapeutics. The company utilizes cutting-edge molecular biology and immunology techniques. The therapeutic areas covered include solid tumor cancers and other various cancers. The patient impact is significant, as these therapeutics aim to provide effective treatment options for patients with cancer. Market positioning is based on developing innovative cancer treatments with the potential to improve patient outcomes. Future opportunities include expanding the pipeline of dsRNA therapeutics and exploring combination therapies. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials to demonstrate efficacy and safety. Partnerships with research institutions and pharmaceutical companies are crucial for advancing the development and commercialization of oncology therapeutics.

This segment focuses on the development of medical devices for interventional cardiology and peripheral vessel applications. The company's primary product in this segment is the Ideal BioStent, a bioabsorbable stent. Research and development activities include the design, testing, and refinement of the bioabsorbable stent. The company utilizes advanced materials science and engineering techniques. The therapeutic areas covered include interventional cardiology and peripheral vessel applications. The patient impact is significant, as the Ideal BioStent aims to provide a safe and effective treatment option for patients with cardiovascular disease. Market positioning is based on developing innovative medical devices with the potential to improve patient outcomes. Future opportunities include expanding the product line and exploring new applications for bioabsorbable stents. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials to demonstrate efficacy and safety. Partnerships with medical device companies and research institutions are crucial for advancing the development and commercialization of cardiology and peripheral vessel applications.